Skip to main content
Top
Published in: International Journal of Hematology 3/2011

01-09-2011 | Images in Hematology

Osteonecrosis of the humeral head

Authors: Moe Kadono, Kazuhiko Kakihana, Ikuyo Endo, Machiko Kawamura, Kazuteru Ohashi, Hisashi Sakamaki

Published in: International Journal of Hematology | Issue 3/2011

Login to get access

Excerpt

A 20-year-old man with a 5-year history of acute lymphoblastic leukemia (ALL) was admitted to our hospital for severe pains in his bilateral groin and right shoulder. He had experienced these pains for 16 months. He underwent allogeneic stem cell transplantation in his second complete remission 13 months prior to hospitalization. He had received corticosteroid therapy both for ALL and for graft versus host disease for a long period (more than 13 months in total), and the total dose of corticosteroids exceeded 20 g in prednisolone equivalent at the time of the hospitalization. X-ray films of the hip joints revealed collapse of bilateral femoral heads. In addition, a subarticular radiolucent line (“crescent sign”) was also observed in an X-ray film of the right shoulder joint (Fig. 1). He was diagnosed with osteonecrosis of the femoral and humeral heads. A magnetic resonance image (MRI) showed a geographical high-intensity area spread to diaphysis, suggesting necrotic changes affecting an extensive area (Fig. 2). He was treated with narcotics for pain. Corticosteroids were reduced as rapidly as possible and maintained at a low dose to treat his adrenal insufficiency. However, his range of motion gradually decreased. Long-term corticosteroid use has been reported to be a risk factor for osteonecrosis of the humeral head, as well as the hip joint. The pathogenesis of steroid-induced osteonecrosis remains unclear, but ischemia from lipocyte hypertrophy or fat embolism has been postulated. The interval between corticosteroid administration and onset of symptom has been reported as between 6 and 18 months. Although the humeral head is the second most commonly affected site in osteonecrosis, it is often unrecognized, and its initial symptoms are often nonspecific. Removal of risk factors can reduce the risk of osteonecrosis to other joints. Thus, the awareness of this complication is very important and imaging studies, including MRI, should be considered in corticosteroid-treated patients with shoulder pain.
Metadata
Title
Osteonecrosis of the humeral head
Authors
Moe Kadono
Kazuhiko Kakihana
Ikuyo Endo
Machiko Kawamura
Kazuteru Ohashi
Hisashi Sakamaki
Publication date
01-09-2011
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2011
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-011-0922-8

Other articles of this Issue 3/2011

International Journal of Hematology 3/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine